

Special Issue

Treatment of Acute Kidney Injury in Cancer Patients: From Theory to Practice

Message from the Guest Editors

Acute kidney injury (AKI) is a common morbidity among cancer patients, with incidence rates reported as high as 50% in certain populations. AKI may result from complications directly related to the malignancy or as an adverse effect of cancer treatment modalities. Over the past decade, cancer therapy has undergone a profound transformation with the advent of targeted therapies, immunotherapy, and cellular therapies. While AKI was historically associated primarily with conventional chemotherapy, it is now increasingly recognized as a complication of these newer, more sophisticated treatment approaches. Effective treatment of AKI in cancer patients demands a multidisciplinary approach involving oncologists, nephrologists, urologists, interventional radiologists, and pharmacists. In this Special Issue, we aim to highlight the evolving landscape of AKI management in patients with both solid tumors and hematologic malignancies, with particular emphasis on kidney injury associated with emerging therapies such as targeted agents, immune checkpoint inhibitors, CAR T-cell therapies, bispecific antibodies (BiTEs), and others.

Guest Editors

Dr. Umut Selamet

Department of Medical Oncology, Dana Farber Cancer Institute,
Harvard Medical School, Boston, MA, USA

Dr. Shveta S. Motwani

Department of Medical Oncology, Dana-Farber Cancer Institute,
Boston, MA, USA

Deadline for manuscript submissions

15 March 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/241969

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)